Successful outcome of ganciclovir-resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors

Transplant International

Volumn 25, Issue 7, 2012, Pages

  Sabe N ^a   Gonzalez Costello J ^a   Rama, I ^a   Niubo J ^a   Bodro, M ^a   Roca, J ^a   Cruzado, J M ^a   Manito, N ^a   Carratalà, Jordi ^a  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

Cytomegalovirus; Ganciclovir resistance; mTOR inhibitors; Solid organ transplantation

Indexed keywords

CYCLOSPORIN; EVEROLIMUS; FOSCARNET; GANCICLOVIR; HEMOGLOBIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; VALGANCICLOVIR;

ABDOMINAL PAIN; ACUTE GRAFT REJECTION; ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BRAIN DISEASE; CASE REPORT; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; GENETIC ANALYSIS; GENITAL ULCER; GRAFT RECIPIENT; HEART RATE; HUMAN; HUMAN CELL; ISCHEMIC CARDIOMYOPATHY; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; LEUKOCYTE; LYMPHOCYTE COUNT; MALE; MONOCYTE; NEPHRECTOMY; ORGAN TRANSPLANTATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PYELONEPHRITIS; RECURRENT DISEASE; THROMBOCYTE COUNT; WEAKNESS; WEIGHT REDUCTION;

ANTIVIRAL AGENTS; CALCINEURIN; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; GANCICLOVIR; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84861989001     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2012.01489.x     Document Type: Article

References (16)

1. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779.
2. de la Torre-Cisneros J, Fariñas MC, Castón JJ, et al. GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant recipients. Enferm Infecc Microbiol Clin 2011; 29: 735.
3. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356: 645.
4. Eid Aj, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transpl 2008; 22: 162.
5. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac- transplant recipients. N Engl J Med 2003; 349: 847.
6. Brennan DC, Legendre C, Patel D, et al. Cytomegalovirus incidence between everolimus versus mycophenolate in De Novo Renal transplants: pooled analysis of three clinical trials. Am J Transplant 2011; 11: 2453.
7. Fortún J, Martín-Dávila P, Pascual J, et al. Immunosuppressive therapy and infection after kidney transplantation. Transpl Infect Dis 2010; 12: 397.
8. Hakki M, Chou S. The biology of cytomegalovirus drug resistance. Curr Opin Infect Dis 2011; 24: 605.
9. Komazin G, Ptak RG, Emmer B, Townsend LB, Drach JC. Resistance of human cytomegalovirus to benzimidazole L-ribonucleoside maribavir maps to UL27. J Virol 2003; 77: 11499.
10. Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogenic stem-cell transplants: a phase 3, double-blind, placebo randomised trial. Lancet Infect Dis 2011; 11: 284.
11. Lau PK, Woods ML, Ratanjee SK, John GT. Artesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection. Clin Infect Dis 2011; 52: 279.
12. Avery RK, Mossad SB, Poggio E, et al. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation 2010; 90: 419.
13. Razonable RR. Immune-based therapies for cytomegalovirus infection. Immunotherapy 2010; 2: 117.
14. Weir MR, Diekmann F, Flechner SM, et al. mTOR inhibition: the learning curve in kidney transplantation. Transpl Int 2010; 23: 447.
15. Moorman NJ, Shenk T. Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication. J Virol 2010; 84: 5260.
16. Ozaki KS, Câmara NOS, Nogueira E, et al. The use of sirolimus in ganciclovir resistant cytomegalovirus infection in renal transplant recipients. Clin Transpl 2007; 21: 675.